selected publications
- Development and testing of a polygenic risk score for breast cancer aggressiveness. NPJ precision oncology. 2023 Academic Article GET IT
- Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study. Research square. 2023 Article GET IT
-
Whole exome sequencing and replication for breast cancer among Hispanic/Latino women identifies FANCM as a susceptibility gene for estrogen-receptor-negative breast cancer.
medRxiv : the preprint server for health sciences.
2023
Article
GET IT
Times cited: 2 - A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer. Breast cancer research and treatment. 2021 Academic Article GET IT
-
The WISDOM study: a new approach to screening can and should be tested.
Breast cancer research and treatment.
2021
Editorial Article
GET IT
Times cited: 10 -
Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.
NPJ breast cancer.
2021
Academic Article
GET IT
Times cited: 415 -
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
NPJ breast cancer.
2021
Academic Article
GET IT
Times cited: 25 -
Medications for Primary Prevention of Breast Cancer.
JAMA.
2020
Review
GET IT
Times cited: 12 -
A Polygenic Risk Score for Breast Cancer in US Latinas and Latin American Women.
Journal of the National Cancer Institute.
2020
Academic Article
GET IT
Times cited: 34 -
Interval breast cancers - insights into a complex phenotype.
Nature reviews. Clinical oncology.
2020
Comment
GET IT
Times cited: 2 -
Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
Breast cancer research : BCR.
2019
Academic Article
GET IT
Times cited: 40 -
A response to "Personalised medicine and population health: breast and ovarian cancer".
Human genetics.
2019
Letter
GET IT
Times cited: 11 -
Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.
Breast cancer research and treatment.
2017
Academic Article
GET IT
Times cited: 18 -
Low-Dose CT Scan for Lung Cancer Screening: Clinical and Coding Considerations.
Chest.
2017
Review
GET IT
Times cited: 30 -
Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
Journal of the National Cancer Institute.
2017
Review
GET IT
Times cited: 141 -
Breast cancer risk prediction using a clinical risk model and polygenic risk score.
Breast cancer research and treatment.
2016
Academic Article
GET IT
Times cited: 91 -
Population-based screening for cancer: hope and hype.
Nature reviews. Clinical oncology.
2016
Review
GET IT
Times cited: 82 -
Detection of ductal carcinoma in situ and subsequent interval cancers.
BMJ (Clinical research ed.).
2016
Editorial Article
GET IT
Times cited: 4 -
Impact of mammographic screening on the detection of good and poor prognosis breast cancers.
Breast cancer research and treatment.
2011
Review
GET IT
Times cited: 64 -
Characterizing the impact of 25 years of DCIS treatment.
Breast cancer research and treatment.
2011
Academic Article
GET IT
Times cited: 84 -
Rethinking screening for breast cancer and prostate cancer.
JAMA.
2009
Academic Article
GET IT
Times cited: 443 -
A role for biomarkers in the screening and diagnosis of breast cancer in younger women.
Expert review of molecular diagnostics.
2007
Review
GET IT
Times cited: 18